- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07946666
A Clinical Trial to Evaluate the Effects of the Synbiotic Dual Cap® on Gastrointestinal Comfort in Adults Initiating GLP-1 or Dual-Incretin Therapy for Weight Loss.
This is a decentralized, single-group, open-label clinical trial evaluating the effects of the Synbiotic Dual Cap® in 40 adults who have initiated GLP-1 or dual-incretin therapy within the preceding 60 days and who are experiencing at least one associated gastrointestinal symptom. All participants will receive the Synbiotic Dual Cap® (1 capsule daily, taken in the morning without food) alongside their existing GLP-1 medication for 12 consecutive weeks.
Participants will complete study-specific questionnaires at four assessment timepoints: Baseline, Week 4, Week 8, and Week 12. No placebo control arm is included; all efficacy comparisons are within-subject against Baseline values. The study is conducted entirely remotely via the Citruslabs digital platform, with the study product shipped directly to participants' homes.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Dimitra Diamantopoulou
- Email: dimitra@epetome.com
Luoghi di studio
-
-
Nevada
-
Las Vegas, Nevada, Stati Uniti, 89101
- Citruslabs
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Adults aged 18-65 years.
- Have initiated a GLP-1 receptor agonist or dual-incretin medication for weight loss (including but not limited to semaglutide, tirzepatide, or liraglutide) within the last 60 days prior to the date of enrollment.
- Self-reported experience of at least one gastrointestinal symptom associated with GLP-1 initiation, including nausea, bloating, constipation, diarrhea, or general digestive discomfort, at the time of screening.
- Currently on a stable GLP-1 dose as directed by their prescribing physician.
- Willing to take one Synbiotic Dual Cap® daily for 12 consecutive weeks alongside their existing GLP-1 medication and complete all questionnaire assessments at Baseline, Week 4, Week 8, and Week 12.
- Willing and able to provide informed consent prior to enrollment.
- In good general health (GLP-1 use and associated weight-related conditions do not disqualify a participant).
- Reside in the United States.
Exclusion Criteria:
- Currently pregnant or breastfeeding (or planning to become pregnant during the study period).
- Currently taking other fibre, probiotic, prebiotic, or synbiotic supplements that cannot be discontinued for the study period.
- Diagnosed with a chronic gastrointestinal condition requiring active prescription medical management - including Crohn's disease, ulcerative colitis, coeliac disease, GERD, or gastroparesis - that would independently confound GI symptom endpoints.
- Use of antibiotics or prescription gastrointestinal medications within the past 30 days prior to enrollment, or intentions to use these medications during the study period.
- Anyone currently participating or planning to participate in another research study during the study period.
- Currently receiving immunosuppressant therapy of any kind.
- Currently undergoing cancer treatment or have had a serious illness requiring hospitalization in the last three months.
- Reside in Hawaii.
- Known allergy or hypersensitivity to any ingredient in the Synbiotic Dual Cap®.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Synbiotic Dual Cap® Arm
|
Participants will take 1 capsule each morning, without food and without a hot drink, for 12 consecutive weeks alongside their existing GLP-1 medication. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Overall Gastrointestinal Comfort
Lasso di tempo: Baseline to Week 12
|
Within-subject change from Baseline in overall gastrointestinal comfort severity, assessed using study-specific questionnaires |
Baseline to Week 12
|
|
Change in Bowel Regularity
Lasso di tempo: Baseline to Week 12
|
Within-subject change from Baseline in bowel regularity, assessed using study-specific questionnaires |
Baseline to Week 12
|
|
Change in Bloating
Lasso di tempo: Baseline to Week 12
|
Within-subject change from Baseline in bloating severity and frequency, assessed using study-specific questionnaires |
Baseline to Week 12
|
|
Change in Constipation
Lasso di tempo: Baseline to Week 12
|
Within-subject change from Baseline in constipation severity and frequency, assessed using study-specific questionnaires |
Baseline to Week 12
|
|
Change in Diarrhea
Lasso di tempo: Baseline to Week 12
|
Within-subject change from Baseline in diarrhea severity and frequency, assessed using study-specific questionnaires |
Baseline to Week 12
|
|
Change in Nausea
Lasso di tempo: Baseline to Week 12
|
Within-subject change from Baseline in nausea severity and frequency, assessed using study-specific questionnaires |
Baseline to Week 12
|
|
Change in Post-Meal Fullness Comfort
Lasso di tempo: Baseline to Week 12
|
Within-subject change from Baseline in comfort with post-meal fullness, assessed using study-specific questionnaires |
Baseline to Week 12
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Participant Perception of Effect on Overall Gastrointestinal Comfort
Lasso di tempo: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on overall gastrointestinal comfort, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
|
Participant Perception of Effect on Bowel Regularity
Lasso di tempo: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on bowel regularity, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
|
Participant Perception of Effect on Bloating
Lasso di tempo: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on bloating, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
|
Participant Perception of Effect on Constipation
Lasso di tempo: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on constipation, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
|
Participant Perception of Effect on Diarrhea
Lasso di tempo: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on diarrhea, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
|
Participant Perception of Effect on Nausea
Lasso di tempo: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on nausea, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
|
Participant Perception of Effect on Post-Meal Fullness Comfort
Lasso di tempo: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on post-meal fullness comfort, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
Collaboratori e investigatori
Sponsor
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema endocrino
- Disturbi della nutrizione
- Malattie metaboliche
- Ipernutrizione
- Peso corporeo
- Segni e sintomi, Digestivo
- Disturbi del metabolismo del glucosio
- Diabete mellito
- Sovrappeso
- Condizioni patologiche, segni e sintomi
- Malattie nutrizionali e metaboliche
- Segni e sintomi
- Obesità
- Diabete mellito, tipo 2
- Nausea
- Stipsi
- Diarrea
Altri numeri di identificazione dello studio
- EPETO-21217
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .